Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/69387
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ripoll Llagostera, Èlia | - |
dc.contributor.author | Merino, Ana | - |
dc.contributor.author | Gomà, Montse | - |
dc.contributor.author | Aran Perramon, Josep M. | - |
dc.contributor.author | Bolaños, Núria | - |
dc.contributor.author | Ramon, Laura de | - |
dc.contributor.author | Herrero Fresneda, Immaculada | - |
dc.contributor.author | Bestard Matamoros, Oriol | - |
dc.contributor.author | Cruzado, Josep Ma. | - |
dc.contributor.author | Grinyó Boira, Josep M. | - |
dc.contributor.author | Torras Ambròs, Joan | - |
dc.date.accessioned | 2016-02-11T14:16:30Z | - |
dc.date.available | 2016-02-11T14:16:30Z | - |
dc.date.issued | 2013-06-14 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/69387 | - |
dc.description.abstract | Lupus nephritis (LN) is an autoimmune disorder in which co-stimulatory signals have been involved. Here we tested a cholesterol-conjugated-anti-CD40-siRNA in dendritic cells (DC) in vitro and in a model of LPS to check its potency and tissue distribution. Then, we report the effects of Chol-siRNA in an experimental model of mice with established lupus nephritis. Our in vitro studies in DC show a 100%intracellular delivery of Chol-siRNA, with a significant reduction in CD40 after LPS stimuli. In vivo in ICR mice, the CD40-mRNA suppressive effects of our Chol-siRNA on renal tissue were remarkably sustained over a 5 days after a single preliminary dose of Chol-siRNA. The intra-peritoneal administration of Chol-siRNA to NZB/WF1 mice resulted in a reduction of anti-DNA antibody titers, and histopathological renal scores as compared to untreated animals. The higher dose of Chol-siRNA prevented the progression of proteinuria as effectively as cyclophosphamide, whereas the lower dose was as effective as CTLA4. Chol-siRNA markedly reduced insterstitialCD3+ and plasma cell infiltrates as well as glomerular deposits of IgG and C3. Circulating soluble CD40 and activated splenic lymphocyte subsets were also strikingly reduced by Chol-siRNA. Our data show the potency of our compound for the therapeutic use of anti-CD40-siRNA in human LN and other autoimmune disorders. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0065068 | - |
dc.relation.ispartof | PLoS One, 2013, vol. 8, num. 6 | - |
dc.relation.uri | http://dx.doi.org/10.1371/journal.pone.0065068 | - |
dc.rights | cc-by (c) Ripoll Llagostera, Èlia et al., 2013 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Malalties del ronyó | - |
dc.subject.classification | RNA | - |
dc.subject.other | Kidney diseases | - |
dc.subject.other | RNA | - |
dc.title | CD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanisms | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 652722 | - |
dc.date.updated | 2016-02-11T14:16:30Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 23799000 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
652722.pdf | 1.74 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License